SCHEMBL4617692

SCHEMBL4617692

O=S(=O)(NCCc1ccccn1)c1cc(S(=O)(=O)c2ccccc2)ccc1C1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ SFRP1 Q8N474 3/20 0.47
▸ HTR6 P50406 1/20 0.43
▸ LMNA P02545 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ ADORA3 P0DMS8 2/20 0.41
▸ ADORA2B P29275 2/20 0.41
▸ ADORA1 P30542 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ PPARG P37231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4617115 0.93 RAB9A (0.45) KDM4EMAPTRAB9ASFRP1LMNA
SCHEMBL4617042 0.85 KDM4E (0.48) KDM4EMAPTRAB9ALMNATSHR
SCHEMBL4617961 0.85 KDM4E (0.47) KDM4EMAPTRAB9ALMNATSHR
SCHEMBL4618877 0.83 RAB9A (0.55) KDM4EMAPTRAB9ASFRP1LMNA
SCHEMBL4617627 0.81 KDM4E (0.46) KDM4EMAPTRAB9ALMNATSHR
SCHEMBL4618304 0.81 SFRP1 (0.71) KDM4EMAPTRAB9ASFRP1
SCHEMBL4618186 0.81 SFRP1 (0.52) KDM4EMAPTRAB9ASFRP1PKM
SCHEMBL4615560 0.81 POLB (0.56) KDM4EMAPTRAB9ASFRP1LMNA
SCHEMBL6102561 0.80 SFRP1 (0.61) KDM4EMAPTRAB9ASFRP1LMNA
SCHEMBL6101959 0.79 SFRP1 (0.53) KDM4EMAPTRAB9ASFRP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 — — EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 — — US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 — — WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 — — EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 — — US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 KDM4E 3044/4885MAPT 4680/4885RAB9A 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback